POU2AF1
Summary:
Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
---|---|---|---|---|---|
POU class 2 associating factor 1 | MIM:601206 | Ensembl:ENSG00000110777 | HGNC:HGNC:9211 | PA33535 | 11q23.1 |
Gene Categories:
TRANSCRIPTION FACTOR COMPLEXGO terms in POU2AF1
Term Type | Evidence Type | GO Term ID | GO Des. |
---|---|---|---|
MF | IDA | GO:0000978 | RNA polymerase II proximal promoter sequence-specific DNA binding |
MF | IMP | GO:0000978 | RNA polymerase II proximal promoter sequence-specific DNA binding |
MF | IMP | GO:0000979 | RNA polymerase II core promoter sequence-specific DNA binding |
MF | TAS | GO:0003712 | transcription coregulator activity |
MF | IMP | GO:0003713 | transcription coactivator activity |
MF | IPI | GO:0005515 | protein binding |
CC | IDA | GO:0090575 | RNA polymerase II transcription factor complex |
CC | IMP | GO:0090575 | RNA polymerase II transcription factor complex |
BP | TAS | GO:0006366 | transcription by RNA polymerase II |
BP | TAS | GO:0006959 | humoral immune response |
BP | IGI | GO:0045944 | positive regulation of transcription by RNA polymerase II |
Gene expression in normal tissue: POU2AF1
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in POU2AF1
Database | Pathway ID | Pathway Des. |
---|
Gene-Drug: Aster Plot
Drug ID | Drug Name | Model Num. |
---|---|---|
iGMDRD151 | CHM-1 | 1 |
iGMDRD126 | Tipifarnib | 7 |
iGMDRD425 | ERASTIN | 2 |
iGMDRD866 | BRD1812 | 5 |
iGMDRD546 | BMS-754807 | 2 |
iGMDRD670 | ML 210 | 5 |
iGMDRD781 | Sirolimus | 5 |
iGMDRD107 | Valdecoxib | 5 |
iGMDRD2 | PK-11195 | 4 |
iGMDRD639 | YK 4-279 | 3 |
iGMDRD679 | Bistramide A | 1 |
iGMDRD513 | BML-259 | 3 |
iGMDRD187 | BRD9876 | 2 |
iGMDRD730 | Kahalalide F | 2 |
iGMDRD188 | Piperlongumine | 3 |
iGMDRD888 | Compound 44 | 10 |
iGMDRD64 | Parbendazole | 3 |
iGMDRD23 | Gossypol | 4 |
iGMDRD356 | PNU-74654 | 4 |
iGMDRD405 | PIK-75 | 3 |
iGMDRD341 | Triacsin c | 5 |
iGMDRD219 | Bax channel blocker | 1 |
iGMDRD698 | Neratinib | 1 |
iGMDRD123 | Isoevodiamine | 1 |
iGMDRD137 | Indisulam | 4 |
iGMDRD202 | Curcumin | 6 |
iGMDRD103 | SN-38 | 4 |
iGMDRD5 | Tyrphostin AG 1478 | 3 |
iGMDRD221 | Tamoxifen | 8 |
iGMDRD105 | Triptolide | 5 |
iGMDRD213 | SMR000068650 | 5 |
iGMDRD286 | Nsc 632839 | 6 |
iGMDRD871 | BRD6368 | 1 |
iGMDRD366 | PI-103 | 5 |
iGMDRD147 | Prima-1 | 2 |
iGMDRD554 | CHEMBL1434137 | 4 |
iGMDRD1008 | SR-II-138A | 3 |
iGMDRD579 | PF750 | 8 |
iGMDRD772 | BRD4770 | 8 |
iGMDRD144 | NSC95397 | 3 |
iGMDRD201 | SKI II | 5 |
iGMDRD446 | LY 2183240 | 1 |
iGMDRD163 | all trans Retinoic Acid | 4 |
iGMDRD193 | Fqi1 | 1 |
iGMDRD297 | Austocystin D | 3 |
iGMDRD634 | SCHEMBL2608041 | 4 |
iGMDRD870 | BRD63610 | 3 |
iGMDRD309 | 17AAG | 1 |
iGMDRD441 | TW 37 | 4 |
iGMDRD318 | PAC-1 | 1 |
iGMDRD885 | Compound 110 | 1 |
iGMDRD887 | Compound 23 citrate | 2 |
iGMDRD60 | Quinoclamine | 2 |
iGMDRD640 | CAY10618 | 3 |
iGMDRD690 | PRIMA-1MET | 7 |
iGMDRD268 | Cerulenin | 5 |
iGMDRD486 | Tosedostat | 4 |
iGMDRD307 | Manumycin A | 2 |
iGMDRD84 | Lovastatin acid | 2 |
iGMDRD148 | Pifithrin-mu | 8 |
iGMDRD701 | NVP-AUY922 | 1 |
iGMDRD351 | GW843682X | 4 |
iGMDRD211 | (1S,3R)-RSL3 | 4 |
iGMDRD132 | (-)-gallocatechin-3-O-gallate | 1 |
iGMDRD6 | AM-580 | 7 |
iGMDRD267 | Oligomycin A | 3 |
iGMDRD481 | Dactolisib | 2 |
iGMDRD882 | CIL41 | 2 |
iGMDRD872 | BRD7137 | 2 |
iGMDRD414 | MST-312 | 1 |
iGMDRD269 | Purmorphamine | 4 |
iGMDRD505 | Pevonedistat | 2 |
iGMDRD300 | Tozasertib | 5 |
iGMDRD82 | Quiflapon | 5 |
iGMDRD353 | PD0325901 | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in POU2AF1